Titlebook: Management of Chemotherapy-Induced Nausea and Vomiting; New Agents and New U Rudolph M. Navari Book 2016 Springer International Publishing

不給啤

First-Generation 5-HT3 Receptor Antagonists,rrent antiemetic therapy conceptually fulfills the true definition of “targeted therapy” as there is significant understanding of pathways involved in emesis as well as specific targeted antagonists to these pathways. This chapter will focus on the 5HT-3 pathway and the specific receptor antagonists

歡騰

Palonosetron,-generation 5-HT. RAs were therapeutically equivalent with several large trials comparing these drugs to one another demonstrating similar efficacy [3, 4]. A plateau in 5-HT. RA activity had been reached. Efforts persisted to find potentially more active agents based on the understanding of the cent

infringe

Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy,, compounding the side effects of chemotherapy. Therefore, high-dose multiple-day chemotherapy with HSCT provides a unique challenge to achieving good antiemetic control and remains one of the neglected areas of antiemetic research. There are difficulties in developing evidenced-based recommendation

細(xì)節(jié)

flammable

VEST

Inordinate

膽小懦夫

Anthrp

Management of Chemotherapy-Induced Nausea and Vomiting978-3-319-27016-6

AORTA